Apoptosis and cutaneous melanoma by Vieira, Ricardo et al.
@[;:(~1iiJ @@IiiJ@@IJ' 2007;22:21-31.
Apoptosis and cutaneous melanoma
Ricardo Vieira, Oscar Tellechea and America Figueiredo
Department of Dermatology, Faculty of Medicine, Coimbra University, Coimbra, Portugal.
Key Words: Melanoma. Apoptosis.
ABSTRACT
Apoptosis, or programmed cell death, is a biological process that eliminates unnecessary,
virus-infected or mutated cells. In that way, it acts as an antitumour event, preventing the
cell immortalization typical of carcinogenesis. Many triggers can induce apoptosis through
an intrinsic or an extrinsic pathway, both leading to the activation of a proteolytic cascade,
which ends in the degradation of several structural proteins and fragmentation of nuclear
DNA.
Proteins from Bcl-2, lAP or p53 families are the most important regulators of apoptosis.
A high rate of p53 gene mutations is observed in most human cancers but only in about
10% of all cutaneous melanomas. However, the disturbance of some intracellular signalling
pathways that occurs com_monly in melanoma is responsible for the down-regulation of p53
protein and also dysfunction of other regulatory proteins (Bcl-2 and lAP families,
Smac/DIABLO and Omi/HtrA2). Therefore, apoptosis cascade evasion and consequent
abnormal cell survival is a common event in cutaneous melanoma. Apoptosis proteins or
genes are possible therapeutic targets to consider in melanoma treatment in the future.
INTRODUCTION
The word apoptosis has its origin in the
Greek term a.1to1t'tOO"lO", which means
autumn leaves fall. Biologically, apoptosis
represents a programmed cell death, a phys-
iological event that leads to a natural selec-
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tion in a cellular level, promoting the elim-
ination of unnecessary, virus-infected or
mutated cells!.
Apoptosis is different from necrosis. The
cell does not become oedematous and cell
content is not released in the interstitial
fluid. This kind of cell death depends on the
energy provided by adenosine-triphosphate
(ATP) molecules. Microscopically, the
fragmentation of nuclear envelope and cell
membranes is observed, leading to the cre-
ation of apoptotic vesicles recognized and
phagocytised by macrophages in an inflam-
mation-free event l .
Apoptosis has a central role in the course
of several biological processes, as organo-
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genesis, haematopoietic and epithelial cell
renewal, cyclic involution of female repro-
ductive organs, atrophy induced by the
absence of growth factors and cell-mediated
cytotoxicity!. It seems to acquire major rel-
evance in antitumour defence, eliminating
transformed cells. Therefore, there are
many proto-oncogens or tumour suppressor
genes encoding proteins that take part in the
apoptotic process. Mutations in critical sites
ofthese genes may cu'fect cell survival, lead-
ing to malignant transformation of many
cell types, including melanocytes2•
THE CASPASES CASCADE
Apoptosis is essentially the result of the
activation in cascade of several particular
proteins named caspases3 (Fig. 1). The cas-
pases are evolutionarily conserved pro-
teases that mediate apoptosis through aspar-
tate-specific cleavage of a large va...ri.ety of
cellular proteins. They are synthesized as
inactive precursors (procaspases) that can
be activated sequentially by proteolytic
cleavage catalysed by other previously acti-
vated caspases. Procaspases activation is a
process submitted to a certain hierarchy.
There are initiator caspases (caspases 2, 8,
9 and 10) hi-at are activated by several trig-
gers and are able to mediate the activation
of effector caspases (caspases 3, 6 and 7).
The final result of the caspases cascade is
the digestion of a wide number of structural
proteins and the degradation of chromoso-
mal DNA. For instance, caspase 3, after
activation by initiator caspases 8 or 9, is
able to cleave gelsolin4, a protein connected
to the actin cytoskeleton and important to
the maintenance of cell structure stability.
Caspase 3 also cleaves the ICAD protein
(inhibitor of caspase-activated DNAse),
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releasing the caspase-activated DNAse
(CAD) into the nucleus. The result is an
intemucleosomic fragmentation of nuclear
DNA in blocks of about 200 base pairs5•
TRIGGERS OF APOPTOSIS
Triggers are needed to start apoptosis6• They
can act through two different pathways (Fig.
1). The transmembrane protein Fas
(CD95)7, the TNFa receptors (TNF-Rl and
TRAIL-R2)8 and enzymes from the lytic
granules of cytotoxic T cells (perforin,
granzyme A fu,d gian.zyme B)l a...re the major
triggers of an extrinsic pathway started in
cell membrane after binding of certain sol-
uble molecules as FasL and TNFa or after
an effector cell-mediated immunologic
response. A different process (intrinsic
pathway) is a consequence of perturbation
of the mitochondrial homeostasis, as occurs
in cells submitted to growth factors priva-
tion or in cells that carry important genomic
damage2• Proteins of Bcl-2 family or p53
family are major apoptosis triggers through
this intrinsic pathway6.
EXTRINSIC PATHWAY
Independently of the trigger, the first event
of the extrinsic pathway is the activation of
procaspase 8. The active caspase 8 subse-
quently activates the effector caspases 3, 6
and 93 (Fig. 1).
When Fas/FasL, TNFa/TNF-RI and
TNFalTRAIL-R2 complexes act as apop-
totic triggers, the activation ofprocaspase 8
is mediated by a COlll.L1JlOn adaptor molecule
named FADD (Fas-associated death
domain). The interaction between FADD
and FaslFasL or TN1<anRAIL-R2 occurs
directly. Conversely, TNFaITNF-RI com-
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Fig. 1• Apoptosis: intrinsic and extrinsic pathways.
plex interacts with FADD using an interme-
diate protein known as TRADD (TNFR 1·
associated death domain)'''.
Finally, FADD and TRADD may also
activate the effector caspases through acti-
vation of procaspase 2, an event mediated
by RIP protein'.
INTRINSIC PATHWAY
Cytosolic cytochrome c release from mito-
chondria is the first step of the intrinsic
pathway. This step is the result of a decisive
change in mitochondrial outer membrane
permeability strictly regulated by BcJ·2 pro-
teins',
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Free cytochrome c in cytosol will interact
with Apaf-l and procaspase 9 to form the
apoptosomic complex9 , The cleavage of
procaspase 9 occurs within the apoptosomic
complex, leading to the production of active
caspase 96. Activation of effector caspases
3,6 and 7 is the final event mediated by the
proteolytic activity of caspase 9 (Fig. 1).
REGULATION OF APOPTOSIS
The most important apoptosis regulatory
proteins are members of Bcl-2, lAP and p53
families.
a) Bcl-2 family:
Bcl-2 is encoded by a gene located in 18q21
and was first described in follicular B lym-
phoma cell lines \vith translocation
t(14;18)1O. Beyond Bcl-2 itself, a wide
number of Bcl-2 family members were
characterized. They can act as proapoptotic
(Bax, Bak, Bad, Bik, Bid, Bok, Bim, Bod,
Bmf, Hrk, Nix, Noxa, PUMA and Bcl-Xs)
or antiapoptotic proteins (Bcl-2, Bcl-w, Bcl-
XL, Mcl-l and Al)l1,12.
All Bcl-2 family members share some
common structural characteristics. Apart
from Bad and Bid, which are generally
found in a soluble form in cytoso]12, Bcl-2
proteins have a C-terminal hydrophobic
domain that gives affinity to the membranes
of several organelles, namely outer mito-
chondrial membrane, endoplasmic reticule
and nuclear envelope ll . They also have
diverse combinations of four different
domains (BHl, BH2, BH3 and BH4),
allowing to classificate the Bcl-2 proteins
into three distinct groups10-12:
• Group I: antiapoptotic proteins with
BHl, BH2, BH3 and BH4 domains
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(Bcl-2, Bcl-XL, Bcl-w, Mcl-l and AI).
• Group II: proapoptotic proteins with
BHl, BH2 and BH3 domains (Bax, Bak
e Bok).
• Group III: proapoptotic proteins with
BH3 domain (Bik, Bid, Bad, Hrk, Bim,
Bod, Bmf, Nix, Noxa e PUMA). Despite
having a BH4 domain, Bcl-XS is com-
monly included in this group.
The mechanism of action of Bcl-2 pro-
teins is not \-vell understood. It is hypothe-
sized that they can be translocated from
mitochondrial intermembrane space to
mitochondrial outer membrane when apop-
tosis is triggered lO• That mobilization occurs
as a result of critical phosphorylations of
Bcl-2 proteins mediated by several kinases,
namely Akt3. Phosphorylated Bcl-2
molecules are able to form homo or het-
erodimers, migrating consecutively to mito-
chondrial outer membrane.
Bcl-2 proteins dimerization can induce
proapoptotic or antiapoptotic events. For
instance, Bcl-2/Bcl-2 homodimer inhibits
cell death. Conversely, the BaxlBax homod-
imer or Bax/Bcl-2 and Bad/Bcl-XL het-
erodimers are proapoptotics lO• Heterodimers
formed by proteins from group III are
always proapoptotics11.
The ability to produce inhibition or stim-
ulation of apoptosis can be elucidated by
ditlerent biological function of Bcl-2 pro-
teins:
1 - Proapoptotic dimers control cyto-
chrome c11 , AIF protein (apoptosis inducer
factor)12, SmacIDIABL013 and OmilHtrA214
release from mitochondria. Cytochrome c,
as previously seen, is part of the apopto-
somic complex. AIF is an apoptosis inducer
with unknown mechanism of action.
SmaclDIABLO and OmilHtrA2 are X-IAP
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(X-linked inhibitor of apoptosis) neutraliz-
ers.
2 - Several antiapoptotic dimmers are
responsible to Apaf-l sequestration, block-
ing the formation of the apoptosomic com-
plex lO ,
3 - Several antiapoptotic dimers create
ionic megachannels between inner and
outer mitochondrial membrane, abolishing
the transmembrane electric potential (pro-
ton motive force) leading to the suspension
of cell energetic production lO ,
b) lAP family
The lAP family is composed by several con-
served proteins (X-lAP, clAP I , clAP2,
NAIP, ML-IAP and surviving), with the
common capacity of inhibiting apoptosis ll •
X-lAP is a potent inhibitor of caspases
proteolytic activity. The proteins clAPI and
cIAP2 are ubiquitin-ligases to Smac/DIA-
BLO, leading to selective proteolysis of that
protein15 •
c) p53 family
The p53 family includes p53, p63 and p73
proteins16, All members of this family have
a highly conserved domain with affinity to
certain DNA sequences, Therefore, all the
p53 family members act as transcription
factors.
P53 is the \rvell kn.o\vn member of L~e fa.."'11-
ily and also the well understood proapop-
totic protein. This molecule induces expres-
sion of a wide number of genes in response
to DNA damage. When DNA damage is
minimal, p53 blocks cell cycle and stimu-
lates expression of DNA-repairing machin-
ery, P53 can also trigger apoptosis intrinsic
pat.lJ.\vay \vhen D~~A damage is severe aJld
irreversible, leading to the cell sacrifice
when critical genomic damage can affect
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the homeostasis of a living tissue or even a
whole organism17 •
The activity ofp53 interferes with several
cellular events as genetic transcription,
DNA synthesis and repair, cell cycle, apop-
tosis and senescence16 • To perform their
actions, p53 binds to the promoter
sequences of its target genes \vith conse-
quent up-regulation of proteins that partici-
pate in these biological processes l8 • Many
genes are recognized targets of p53, as
many cell cycle regulators (p2ICipl, cyclin
E and TGF~), apoptosis regulators (Bax,
PIG-3, Bak, Noxa, PUMA, lAP, Fas) and
DNA-repair enzymes (BTG2 e DDB2).
The proapoptotic function of p53 is
increased by two proteins known as ASPP I
and ASPP2 (inhibitor of apoptosis-stimu-
lating protein for p53 I and 2). ASPPI and
ASPP2 are able to bind to the functional
domain of p53 increasing its affinity to the
promoters of genes encoding important
proapoptotic proteins. Independently of
p53, ASPPI and ASPP2 can also induce
apoptosis acting by the same way with
DNA-binding domains of p63 or p73 16 •
The IASPP protein (inhibitor of apopto-
sis-stimulating protein for p53) is a direct
inhibitor of p5316. ~y1D~y12 (mouse double-
-minute 2 protein) is another important
inhibitor of p53, acting indirectly as ubiqui-
tin-ligase that decreases p53 half-life
through ubiquitin-dependent proteolysis19•
RELEVANCE IN THE GENESIS OF
MELANOMA
Apoptosis malfunction with cell immortal-
ization is a common occurrence in human
1 2 'T'k~ ~"':l ~~~.~:~ ~ln ..~ n ~n:~~neop~asms . .l.1J~ p...J.J P1UL~1U play.., a U1QJUl
role in human carcinogenesis as it is
mutated in about 35% to 40% of all human
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cancers l6 • These mutations are even more
common in skin squamous-cell carcinomas
(more than 90%) or in basal-cell carcino-
mas (about 40% to 50%)20. However, in
cutaneous melanoma, p53 is mutated only
in a rate of about 10%21. This low rate does
not mean that p53 has only a minor role in
melanoma carcinogenesis. In fact, inactiva~
tion of the p53 protein can result from other
events than loss-of-function mutations in
the p53 gene. For instance, mutations of the
tumour suppressor gene CDKN2A are fre-
quent in cutaneous melanoma (40% in
familial melanomas and 10% in sporadic
melanomas). This gene encodes two pro-
teins (P14ARF and p16!NK4a) mainly responsi-
ble for cell cycle regulation. Nevertheless,
p l4ARF is also the most important inhibitor
of MDM2. Its loss involves a subsequent
increase in MDM2 function resulting in p53
destruction. In this circumstance, mutations
of the p53 gene would result superfluous21 .
The most common way to induce cell sur-
vival in melanoma cells is related with the
disturbance of several signalling path-
ways22,2J. As a major example, frequent up-
regulation of signalling through
RafiMEK/ERK and PI3K/Akt pathways
leads to the inactivation of the proapoptotic
Bad protein. This event is a consequence of
Bad phosphorylation catalyzed by two sig-
nalling kinases, respectively Raf-l (inter-
mediary of Raf/MEKIERK signalling path-
way) and Akt3 (intermediary of PI3K1Akt
signalling pathway)Z4. Akt3 also phospho-
rylate procaspase 9, producing a proteoly-
sis-resistant protein25 •
The great importance of cell survival in
melanoma cells is unquestionable.
According to this supposition, some anti-
-cancer drugs are being developed in order
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to induce tumour cells to enter in apoptosis.
One of these drugs (genasense or
oblimersen) is an oligonucleotide a...l1tissense
sequence that blocks the initiation codon of
Bcl-2 mRNA. In vitro studies were very
promising and encouraged the performance
of a phase III double-blind clinical trial with
771 stage IV melanoma patients, comparing
one arm treated with dacarbazine alone with
another arm treated with an association of
dacarbazine and genasense. The survival
was larger in this second arm as was the
global response rates (11.7% versus
6.8%)26. However, the overall survival was
not affected by dacarbazine and genasense
regimen. In that way, the potentiality of tar-
geting apoptotic proteins to treat cancer is
even an attempt to explore in the future.
CONCLUSIONS
Apoptosis dysfunction is apparently a very
common event in melanoma as in many
human cancers. P53 is generally the most
affected tumour suppressor gene related
with non-melanoma skin cancer but not
with cutaneous melanoma. Despite the low
rate of p53 mutations, a functional down-
-regulation of p53 protein is frequently
observed in melanoma cell lines as a conse-
quence of disturbance of some intracellular
signalling pathways.
Apoptotic proteins and their genes are
possible therapeutic targets in the future.
The design of new drugs able to block
abnormal molecules will represent an
attempt to correct the typical immortality of
tumour cells, directly inducing cell death
within the tumour.
 
